Milestone Scientific AI Stock Analysis
Want to see MLSS full AI Analyst Report?
Milestone Scientific (MLSS) AI Stock Analysis
Milestone Scientific
(NYSE MKT:MLSS)
MLSS scores in the low-50s primarily due to weak financial performance (ongoing losses and negative free cash flow) and bearish-to-weak technicals. Offsetting this, the earnings call showed meaningful operating momentum (revenue growth, reimbursement progress, clinical validation, and reaffirmed guidance), while valuation is constrained by negative earnings and corporate actions add flexibility but increase dilution risk.
Milestone Scientific (MLSS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $26.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 113.36K
- Price to Earnings (P/E)
- -6.5
- Beta (1Y)
- 1.00
- Revenue Growth
- 3.72%
- EPS Growth
- 43.78%
- Country
- US
- Employees
- 15
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Milestone Scientific Business Overview & Revenue Model
Company Description
Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a pre...
Milestone Scientific Earnings Call Summary
The call presented multiple clear operational and commercial wins — robust revenue growth, a large percentage increase in medical segment revenue, important Medicare reimbursement milestones, strong third-party clinical validation (91% reduction in complication odds), new federal distribution access, and improved expense discipline that reduced net loss. Offsetting these positives are margin pressure from increased product/import costs, a non-recurring ~ $500K international order that tempers near-term sequential revenue (Q3 guide below Q2), medical revenue still coming from a small base, staffing capacity constraints for lead and reimbursement follow-up, and a modest cash balance that could require monitoring. On balance the call emphasized measurable commercial progress and validation and management provided a path to scale reimbursement and federal channels, while acknowledging operational headwinds to be managed.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reaffirmed 2026 revenue guidance of $9.8M–$10.2M and said CompuFlo should grow faster than the overall business, after reporting Q2 revenue of $2.8M (up 22% YoY) and H1 revenue of $5.0M (up ~9.8% YoY), with the base business contributing $2.4M and roughly $500K of upside from international orders; Medical segment revenue grew 231% YoY in Q2, supported by a $325 payment established under Novitas and First Coast covering 3 jurisdictions and 13 states (≈30–35% of the U.S. population), while the company noted a UTMB study showing a 91% reduction in odds of composite complications and CompuFlo use at >40 academic centers; Q2 gross profit was $1.9M (67.2% margin), operating expenses were ≈$3.0M (down ~$0.5M or 4.2%), Q2 net loss was $1.1M (vs $1.5M prior), six‑month gross profit was $3.5M (69.4%), six‑month OpEx was $5.4M (down ~$1.4M or 20%), cash was $2.1M with $3.7M working capital and $466K convertible debt (plus a $2.51M private placement in April), the company expects Q3 to be seasonally slower and guided Q3 revenue to roughly $2.3M–$2.5M (noting two large Q2 international orders are not expected to recur), and highlighted commercial traction with 150–200 leads/month (150–200), >40 qualified ASPN leads, a Red One distribution channel reaching ~18M veterans/military beneficiaries, and a plan to take government orders in Q4.
Milestone Scientific Financial Statement Overview
Summary
Revenue is improving and gross margins are strong (~70%), but profitability and cash generation remain major issues (TTM net margin roughly -44% and negative operating/free cash flow around -$0.64M). Leverage is modest (debt-to-equity ~0.18), yet equity has eroded materially over time, keeping the financial profile high-risk until sustained profitability and positive cash flow are achieved.
Income Statement
24NegativeBalance Sheet
53NeutralCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.42M | 8.97M | 8.63M | 9.83M | 8.81M | 10.30M |
| Gross Profit | 6.56M | 6.33M | 6.43M | 6.79M | 4.90M | 6.31M |
| EBITDA | -3.92M | -5.51M | -4.58M | -6.83M | -8.63M | -6.79M |
| Net Income | -4.14M | -5.72M | -4.71M | -6.93M | -8.71M | -6.82M |
Balance Sheet | ||||||
| Total Assets | 8.35M | 7.81M | 9.80M | 11.37M | 13.70M | 19.81M |
| Cash, Cash Equivalents and Short-Term Investments | 2.07M | 1.11M | 3.26M | 5.95M | 8.72M | 14.76M |
| Total Debt | 615.70K | 1.02M | 349.05K | 395.98K | 497.04K | 586.59K |
| Total Liabilities | 4.88M | 4.99M | 3.96M | 3.36M | 3.70M | 3.59M |
| Stockholders Equity | 3.47M | 2.81M | 5.83M | 8.01M | 10.23M | 16.37M |
Cash Flow | ||||||
| Free Cash Flow | -642.63K | -2.93M | -2.93M | -5.33M | -6.04M | -4.03M |
| Operating Cash Flow | -642.64K | -2.92M | -2.92M | -5.33M | -6.03M | -4.02M |
| Investing Cash Flow | -15.12K | -15.12K | 2.97M | -2.97M | -8,527 | -15.19K |
| Financing Cash Flow | 1.45M | 786.34K | 233.77K | 2.56M | -8,544 | 4.57M |
Milestone Scientific Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLSS, the sentiment is Negative. The current price of 0.31 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.37, and below the 200-day MA of 0.35, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 36.97 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLSS.
Milestone Scientific Risk Analysis
Milestone Scientific disclosed 49 risk factors in its most recent earnings report. Milestone Scientific reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksMilestone Scientific Peers Comparison
Overall Rating
NEPH64Neutral
POCI51Neutral- MLSS51Neutral
FEMY45Neutral
RVP44Neutral
NXGL39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NEPH | 64Neutral | $34.24M | 17.16 | 16.83% | ― | 20.36% | 26.09% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| POCI | 51Neutral | $55.74M | -10.90 | -23.92% | ― | 65.16% | 45.07% |
| MLSS | 51Neutral | $26.46M | -6.49 | -149.08% | ― | 3.72% | 43.78% |
| FEMY | 45Neutral | $11.98M | -0.33 | -225.98% | ― | 21.86% | 73.27% |
| RVP | 44Neutral | $16.59M | -4.61 | -4.59% | ― | -11.16% | 59.85% |
| NXGL | 39Underperform | $11.00M | -0.29 | -133.10% | ― | 3.38% | -78.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MLSS | Milestone Scientific Inc | 0.31 | -0.07 | -18.47% | |
| RVP | Retractable Technologies | 0.55 | -0.26 | -31.60% | |
| POCI | Precision Optics Corporation, Inc. | 5.05 | 0.22 | 4.55% | |
| NEPH | Nephros, Inc. | 3.07 | -1.35 | -30.54% | |
| FEMY | Femasys, Inc. | 1.50 | -15.03 | -90.93% | |
| NXGL | Nexgel, Inc. | 4.24 | -33.76 | -88.84% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026